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Abstract
Background: The tetracycline-inducible gene regulation system is a powerful tool that allows temporal and dose-
dependent regulation of target transgene expression in vitro and in vivo. Several tetracycline-inducible transgenic
mouse models have been described with ubiquitous or tissue-specific expression of tetracycline-transactivator (tTA),
reverse tetracycline-transactivator (rtTA) or Tet repressor (TetR). Here we describe a Tet-On transgenic rat that
ubiquitously expresses rtTA-M2 driven by the murine ROSA 26 promoter.
Results: The homozygous rat line (ROSA-rtTA-M2) generated by lentiviral vector injection, has a single integration
site and was derived from the offspring of a genetic mosaic founder with multiple transgene integrations. The
rtTA-M2 transgene integrated into an intron of a putative gene on chromosome 2 and does not appear to affect
the tissue-specificity or expression of that gene. Fibroblasts from the ROSA-rtTA-M2 rats were transduced with a
TetO7/CMV-EGFP lentivirus and exhibited doxycycline dose-dependent expression of the EGFP reporter transgene,
in vitro. In addition, doxycycline-inducible EGFP expression was observed, in vivo, when the TetO7/CMV-EGFP
lentivirus was injected into testis, kidney and muscle tissues of ROSA-rtTA-M2 rats.
Conclusions: This conditional expression rat model may have application for transgenic overexpression or
knockdown studies of gene function in development, disease and gene therapy.
Background
Rats are widely used models of basic biology, human
physiology and disease, but the study of genes and their
f u n c t i o n si nr a t sl a g sf a rb e h i n dp r o g r e s si nm i c e .D u r -
ing the 1980s, mice became the predominant model for
functional genetic studies because progress culturing
and manipulating eggs and embryos [1] of this species
facilitated pronuclear injection and blastocyst injection,
ex vivo [2-8]. In addition, development of germline
competent embryonic stem cells [9,10] enabled complex
and targeted genetic manipulations (e.g., knockin and
knockout). In contrast, pronuclear injection is generally
considered less efficient in rats [11], germline competent
ES cells were only recently established for this species
[12,13] and there are no reports of gene targeting in ES
cells to produce knockout rats.
Rats are particularly amenable to laboratory investiga-
tions because of their intermediate size, short gestation
and high fecundity. Rats are about ten times larger than
mice and thus, provide more tissue and are more amen-
able to surgical manipulation, vascular access and
repeated sampling. Due in part to these features, the rat
is a valuable model for transplantation, cardiovascular,
hypertension, neuroscience, pharmacology, diabetes,
obesity, aging and cancer [14,15]. Furthermore, there is
over a century of phenotypic and physiological data on
anatomy, physiology and disease for various inbred rat
models [15,16]. Combining these data with improved
genetic and genomic resources will provide unprece-
dented opportunities for functional genetic studies in
this species. Recognizing this opportunity, NIH
has funded the Rat Expressed Sequence Tag (EST)
Program, the Rat Genome Program and the Rat Gen-
ome Database and established the Rat Resource
Research Center (RRRC; http://www.nrrrc.missouri.edu)
during the past decade [17]. This NIH effort is
matched by the National Bio Resource Project for the
Rat (NBRP-Rat; http://www.anim.med.kyoto-u.ac.jp/
NBR/) in Japan and rat resource repositories in Europe
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euratools.eu). Thus, there is a strong impetus to expand
the transgenic tools for this species.
Production of transgenic rats by pronuclear injection
[18,19] is now routine, albeit less efficient than for the
most efficient mouse strains [14]. In addition, lenti-
viruses [20,21], sperm [22] and spermatogonial stem
cells [23,24] have recently been exploited as vehicles for
modifying the rat germline and producing transgenic
rats with efficiencies ranging from 6-46%. Although
germline competent ES cells have not yet been used to
produce knockout rats, transgenic expression of short
hairpin RNAs (shRNA) or microRNAs (miRNA) allow
knockdown of target gene expression for investigations
of gene function [25,26]. Chemical mutagenesis of germ
cells by N-ethyl-n-nitrosourea (ENU) can introduce ran-
dom point mutations in rat genome, but the require-
ment of labor-intensive screening analysis and high cost
limits its application [27,28]. Finally, pronuclear injec-
tion of zinc-finger nucleases is a new tool to generate
knockout rats [29]. Thus, several approaches are now
available to modify and manipulate the rat genome/tran-
scriptome and expand the transgenic resources for this
species.
Some transgenic manipulations have developmental
effects (e.g., embryonic lethality), which preclude studies
in adult tissues. These problems can be circumvented
through the use of tissue-specific and/or conditional
promoters. Several inducible promoter systems have
been described, including those regulated by tetracycline
[30], ecdysone [31], rapamycin [32], or steroids [33].
The tetracycline (Tet)-inducible system has been the
most extensively characterized and allows conditional
regulation of gene expression in vitro [30] and in vivo
[34,35]. Tet-repressor (TetR), Tet transactivator (tTA)
and reverse Tet transactivator (rtTA) systems mediate
tetracycline (or doxycycline)-controlled transactivation
of a second recombinant transgene located downstream
of composite promoters that contain tet operator
(TetO) sequences (e.g., TetO7/CMV). To date, over 100
different tetracycline-regulated transgenic mouse lines
have been described (reviewed at the Tetmouse Base,
http://www.zmg.uni-mainz.de/tetmouse/index.htm). In
contrast, only a few rat lines have been generated,
expressing either tTA [36-38] or rtTA [39]. To facilitate
loss-of-function studies, two conditional (inducible)
transgenic rats have been described in which TetR/TetO
system is employed to regulate expression of an shRNA
[40,41].
Here we describe the generation and characterization
of a novel Tet-On transgenic rat. This transgenic line
was generated by injecting lentiviral vectors containing
the ubiquitous ROSA26 promoter [42] and an rtTA-M2
transgene under the zona pellucida of one-cell rat
embryos, as previously described [20]. rtTA-M2 is a
mutant of rtTA that has increased stability, reduced
background expression in the absence of doxycycline
(Dox, tetracycline analog) and improved inducibility in
the presence of Dox [43]. ROSA-rtTA-M2 rats gener-
ated in this study exhibit wide-spread expression of
rtTA-M2 and Dox-regulated transactivation of a target
TetO7/CMV-EGFP transgene. The TetO7/CMV compo-
site response element is commonly referred to as pTet
or TRE.
Results
The ROSA26-rtTA-M2 lentiviral vector (Figure 1A) was
injected under the zona pellucida of 219 1-cell S/D rat
embryos. A total of 179 injected embryos (81.7%)
cleaved to produce 2-cell embryos after overnight cul-
ture and these were transferred to the oviducts of 3
pseudopregnant S/D female rats. These transferred
embryos resulted in 35 live progeny and RT-PCR results
(not shown) indicated that 12 (34%) of these carried the
ROSA26-rtTA-M2 transgene. Four founder progeny
(Tg124, Tg129, Tg135, Tg144) were maintained for
further characterization. Southern blot analyses indi-
cated that founder animals had between two (Tg135)
and six (Tg129) proviral insertion sites (Figure 2A). The
intensity of bands corresponding to independent inser-
tions were varying in some cases, indicating they could
be genetic mosaics.
Cultures of tail fibroblasts were established for each
founder animal and were transduced with a lentivirus
containing the TetO7/CMV-EGFP reporter transgene
(Figure 1B) in the presence of Dox. EGFP fluorescence
was observed 48 hours later in fibroblasts from two
founders (Tg129 and Tg144) using an epifluorescent
microscope (Figure 2B). EGFP expression was not
observed in the absence of Dox (not shown). The foun-
der Tg144, with five proviral integrations and the most
robust Dox-dependent EGFP expression, was selected to
establish a ROSA26-rtTA-M2 transgenic rat line. This
founder was bred to wild type S/D females to produce
F1 transgenic progeny and segregate the independent
integration sites.
All transgene insertions from founder (F0) 144 were
transmitted through the germline and four different inte-
gration patterns were recovered in the F1 progeny (Fig-
ure 3A). Cultures of tail fibroblasts established for each
of the F1 progeny were transduced with Lenti-TetO7/
CMV-EGFP and maintained in the presence or absence
of Dox for 48 hours. Western blot analyses demonstrated
Dox-dependent expression of the EGFP reporter gene
from progeny with each integration pattern and revealed
that expression level was not dependent on the number
of integration site s( F i g u r e3 B ) .I n d e e d ,F 1p r o g e n yw i t h
only a single integration (integration pattern D) exhibited
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(Figure 3B). F1 female 1089 and F1 male 1088 had a
common single integration site corresponding to integra-
tion pattern D and were bred together to establish the
homozygous transgenic line ROSA-rtTA-M2-1089/1088
(ROSA-rtTA-M2). Cultures of tail fibroblasts established
from homozygous F2 progeny exhibited tight regulation
and Dox dose-dependent induction of the TetO7/CMV-
EGFP reporter transgene (Figure 4A). Immunocytochem-
ical analysis of GFP expression in cultures of tail
fibroblasts from the F2-F5 generation of homozygous
ROSA-rtTA-M2 rats demonstrated that the transgene is
stably integrated, transmitted through the germline and
not silenced (results from the F5 generation are depicted
in Figure 4B-E). Rats from this line exhibited normal fer-
tility and appeared phenotypically normal. Real-time PCR
analysis was used to quantitatively evaluate rtTA-M2
expression in multiple tissues. From the twelve tissues
analyzed, the highest rtTA-M2 expression was observed
in skeletal muscle, followed by liver, kidney, brain, heart,
adrenal, lung, intestine, testis, uterus, ovary and spleen
(Figure 4F).
Linker-mediated PCR was used to amplify the junc-
tions between chromosomal DNA and the ROSA26-
rtTA-M2 transgene (see Additional File 1: Figure S1 for
summary of Linker-mediated PCR). Sequence compari-
son with the NCBI rat genomic database indicated that
the transgene integrated into intron 11 of a putative
gene (GeneID: 310880) on chromosome 2 (Figure 5A).
The integration site was further confirmed by PCR
amplification of the junctions between genomic and
transgene DNA (Figure 5B). Amplification of the 5’
junction produced a 4 kb product (Figure 5B, lane 2),
which was cleaved to the expected smaller products by
EcoR1 (Figure 5B, lane 3) and Spe1 (Figure 5B, lane 4).
RT-PCR was performed to compare expression of the
putative gene (GeneID: 310880) in tissues of wild type
and ROSA-rtTA-M2 rats. Expression of the putative
gene was observed in heart, ovary and testis, but not
brain, kidney or liver. There were no differences in
expression of the putative gene between wild type and
transgenic rats (Figure 5C).
To test the function of the rtTA-M2 transgene in vivo,
the TetO7/CMV-EGFP reporter lentivirus was injected
into testes, skeletal muscle (hind leg) and kidney of
ROSA-rtTA-M2 rats maintained with or without Dox in
the drinking water. Based on real time PCR results in
Figure 4F, these represent low (testis), medium (kidney)
and high (skeletal muscle) expressing tissues. Dox-
dependent expression of EGFP was observed in testis
(Figure 6A-D), skeletal muscle (Figure 6E-F) and Kidney
(Figure 6G-H). EGFP expression was not observed for
any of these tissues in the absence of Dox (Figure 6A,
C, E and 6G).
Discussion
In this study, we generated a “Tet-On” transgenic rat
line that exhibits ubiquitous expression of the modified
Figure 1 pLenti-Rosa26-rtTA-M2 and pLenti-TetO7/CMV-EGFP lentiviral vectors. Replication-deficient lentiviral vectors feature a self-
inactivating 3’UTR and a CMV enhancer replaces the U3 region of the 5’UTR. WRE: woodchuck hepatitis posttranscriptional regulatory element.
A. Expression of rtTA-M2 is driven by the ubiquitous Rosa-26 promoter. B. Expression of EGFP is under control of a seven repeat Tet operator
and CMV minimal promoter (TetO7/CMV). In the presence of doxycycline (yellow triangles), The rtTA-M2 protein (blue ovals) encoded by the
construct in (A) binds the TetO7 operator and transactivates EGFP expression from the construct in (B).
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under control of the ROSA26 promoter. As detailed in
the introduction, it is the dawn of a new era for biologi-
cal investigations using the rat model. Vast phenotypic
and physiological data generated over the past century
on rat anatomy, physiology and disease can now be
combined with new genetic resources to enable state of
the art functional genetic investigations. The best way to
s t u d yg e n ef u n c t i o ni st h r o u g ht h eg e n e r a t i o no fg a i n -
of-function (transgenic) or loss-of-function (knock-out,
Knock-down) animal models. The functions of over
5,000 genes have been investigated using transgenic or
knockout approaches in the mouse (Mouse Genome
Database, [44]). Considerably fewer genes in the rat gen-
ome have been studied functionally using gain-of-func-
tion or loss-of-function mutants. This deficit in rats may
Figure 2 Integration site(s) and transgene expression analysis of rtTA-M2 transgenic rat founders. A. Southern blot analysis. Genomic
DNA from four transgenic founder animals (Tg124, Tg129, Tg135, Tg144) was digested with EcoRI and hybridized with rtTA-M2 cDNA. B.
Expression and function analysis of the rtTA-M2 transgene. Tail fibroblasts from the four rtTA-M2 transgenic founders were transduced with
Lenti-TetO7/CMV-EGFP and cultured in the presence of Dox (500 ng/ml). EGFP expression was observed by immunocytochemistry 48 hours post-
transduction using an epifluorescent microscope and a FITC filter cube. EGFP expression was observed in transgenic founders, Tg129 and Tg144,
indicating expression of the rtTA-M2 transgene and transactivation of the TetO7/CMV-EGFP transgene. EGFP expression was not detectable in tail
fibroblasts from transgenic founders Tg124 and Tg135. EGFP expression was not observed in fibroblasts from any of the transgenic founders if
Dox was not added. Bar = 20 μm.
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approaches in rat are less efficient than in mouse and in
part from the fact that germline competent rat embryo-
nic stem (ES) cell lines were not available, until recently
[12,13]. To date, there are no reports that these rat ES
cells have been used for targeted inactivation of specific
genes and generation of knockout rats. However, Geurts
and co-workers recently reported the generation of tar-
geted mutant rats by injection of zinc finger nucleases
in embryos. This may constitute a powerful approach
for generating loss-of-function rat models and has the
potential for widespread application if it can be com-
bined with homologous recombination [29,45].
Several approaches have been used to generate trans-
genic rats, including pronuclear injection, ICSI [22,46],
spermatogonial stem cells [23,24] and lentiviral injection
into one cell embryos [20,21]. These approaches have
varying efficiencies, strengths and weaknesses. No single
approach is superior for every application. In the current
study, Tet-On transgenic rats were generated by inject-
ing lentiviral vectors (carrying the ROSA-rtTA-M2
transgene) under the zona pellucida of one cell embryos.
This approach was initially described for rats by Lois
and co-workers [1] and is significantly more efficient
(34% for the current study) than the standard pronuc-
lear injection method. Lentivirus-mediated transgenesis
does have limitations. The transgene cassette inserted
between the viral LTRs is typically limited to less than
10 Kb. Viral genomes with larger transgenes are not
packaged efficiently, leading to decreased viral titer. The
ROSA-rtTA-M2 transgene cassette was approximately
1.5 Kb, well within the capacity of the lentiviral genome.
A second limitation of lentivirus-mediated transgen-
esis is that each lentiviral integration contains a single
copy of the transgene, rather than head to tail arrays of
multiple transgenes that can occur after pronuclear
Figure 3 DNA and transgene expression analysis of F1 progeny from transgenic founder Tg144. A. Southern blot analysis. Samples of
genomic DNA from Tg144 and its F1 progeny were digested with EcoRI and hybridized with rtTA-M2 cDNA. Founder (F0) and first generation
progeny (F1) identification numbers are indicated at the top of each lane. Four different transgene integration patterns were passed to the F1
progeny of transgenic founder Tg144 and are identified by letter at the bottom of each lane (a, b, c, d). F1 progeny carried one to four
integrations of the rtTA-M2 transgene. B. Fibroblasts from F1 progeny with each of the four integration patterns were transduced with Lenti-
TetO7/CMV-EGFP and cultured with or without Dox (Dox +/-). EGFP expression was evaluated by Western blot analysis 48 hours after viral
transduction. The blot was stripped and reprobed with b-actin antibody as a loading control.
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gene expression are required. Also, multiple integrations
in a founder generated by lentiviral injection will be seg-
regated in the next generation. For example, founder
Tg144 with five transgene integrations produced pro-
geny with four different integration patterns (Figure 3A).
Integration site effects were also revealed in the F1 pro-
geny from founder Tg144. F1 progeny with integration
pattern d (single integration) exhibited stronger expression
of the rtTA-M2 transgene than F1 progeny with integra-
tion pattern b (four integrations; Figure 3B). Expression of
rtTA-M2 from the single homozygous integration in the
ROSA-rtTA-M2 line was sufficient to drive expression
from the Lenti-TetO7/CMV-EGFP reporter gene, in vitro
(Figure 4A-E) and in vivo (Figure 6).
Functional genetic studies can be complicated if the
genetic modification causes an embryonic lethal pheno-
type. This complication can be circumvented by using
Figure 4 Characterizing rtTA-M2 transgene expression from homozygous ROSA26- rtTA-M2-1089/1088 transgenic rats (single
integration). A homozygous rtTA-M2 transgenic rat line (ROSA26-rtTA-M2-1089/1099; renamed ROSA-rtTA-M2) was established by breeding F1
Tg1088 (male) and F1 Tg1089 (female), which each exhibited a single common integration of the ROSA26-rtTA-M2 transgene. A. Doxycycline
dose response analysis. Fibroblasts from ROSA-rtTA-M2 F2 progeny were transduced with Lenti-TetO7/CMV-EGFP and cultured in medium
containing different concentrations of Dox (0 to 1000 ng/ml). Western blot analyses were used to evaluate EGFP expression. The blot was
stripped and reprobed with b-actin antibody as a loading control. B-E. rtTA-M2 gene was stably transmitted. Fibroblasts from the F5 generation
of homozygous ROSA-rtTA-M2 rats were transduced with Lenti-TetO7/CMV-EGFP and cultured in medium without (B and C) or with (D and E)
Dox (500 ng/ml). EGFP expression was observed by immunocytochemistry 48 hours post-transduction (Bar = 20 μm). F. Real time-PCR analysis to
determine tissue distribution of rtTA-M2 expression from ROSA-rtTA-M2 rats. rtTA-M2 expression in each tissue is presented relative to the rtTA-
M2 expression in the testis. The whiskers represent the standard errors. b-actin was used as an internal control for each tissue.
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transgene to be activated at specific times of develop-
ment. In the current study we utilized a mutant of the
reverse Tet transactivator (rtTA-M2; [43]) that activates
gene expression by binding to the Tet operator (TetO)
in the presence of doxycycline (Tet-On). The M2 itera-
tion of rtTA is stable in mammalian cells (HeLa), func-
tions at a 10-fold lower concentration of Dox than rtTA
and causes no background expression [43]. We found
that rtTA-M2 exhibited similar characteristics in rat pri-
mary fibroblasts and in vivo using the ROSA-rtTA-M2
line. This transgenic rat line has been bred to homozyg-
osity and has been propogated to the fifth generation
without silencing of transgene expression. Early this
year, three groups have reported generating transgenic
rats by driving TetR expression with the chicken b-actin
or ubiquitin promoters [38,41] or tTA by the chicken b-
actin promoter [40]. In addition, Konopka and cowor-
kers [39] generated a “Tet-On” transgenic rat in which
rtTA is driven by the EF1a promoter. The EF1a promo-
ter is typically expected to cause ubiquitous expression,
but functional rtTA expression (indicated by activation
of a TetO/CMV-EGFP reporter) was limited to the testis
in that study.
Conclusion
The ROSA-rtTA-M2 Tet-On rat line may provide a ver-
satile tool for functional genetic studies because rtTA is
ubiquitously expressed and can regulate conditional
expression of target transgenes, in vitro or in vivo. In
Figure 5 Rosa-rtTA-M2 integrated into a putative gene on chromosome 2. A. Rosa-rtTA-M2 provirus inserted into intron 11 of putative
gene (GeneID: 310880) on chromosome 2. E: Exon. B. Genomic PCR using primers from Exon 10 (P1) and vector (P2) verified this integration.
Lane M: 1 Kb DNA ladder; lane 2, no digestion; lane 3, EcoRI digestion; lane 4, Spe I digestion; lane 5, wide type rat DNA). C. Detection of the
putative endogenous gene expression in rat tissues by RT-PCR. Reverse transcription was performed with an oligo (dT)17 primer. The
endogenous transcript was amplified using primers from exon 10 (P1) and exon 13 (P3) of this putative gene. M2: ROSA-rtTA-M2 rat; wt: wild
type rat.
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Page 7 of 12Figure 6 Evaluation of EGFP expression in tissues from ROSA-rtTA-M2 transgenic rat. Lenti-TetO7/CMV-EGFP was injected into the testis,
hind leg skeletal muscle or kidney of ROSA-rtTA-M2 rats without (A, C, E and G) or with (B, D, F and H) Dox in their drinking water (0.5 mg/ml).
A-B. Immunohistochemical analysis of EGFP expression in histological section of testicular seminiferous tubule. Counterstain: DAPI. C-D.
Immunohistochemical analysis of EGFP expression in whole mount of testicular seminiferous tubule. E-F. Immunohistochemical analysis of EGFP
expression in skeletal muscle. G-H. Immunohistochemical analysis of EGFP expression in Kidney. Counterstain: hematoxylin. Bar = 50 μm (all
panels).
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gene was placed downstream of Tet operator sequences
and CMV minimal promoter (TetO7/CMV) in a lenti-
viral vector. Similar constructs can be used for condi-
tional over-expression or knock-down (using shRNA or
miRNA sequences [40]) by replacing EGFP with any
transgene of interest. Functions of target genes can be
evaluated in vivo by injecting the target transgene into
tissues of ROSA-rtTA-M2 rats as demonstrated here or
by breeding ROSA-rtTA-M2 rats to a second transgenic
line containing the TetO7/CMV minimal promoter and
a transgene of interest. The utility and flexibility of the
Tet regulatory system in rats will be increased by conti-
nuing to generate various iterations of Tet repressors,
Tet transactivators and Tet responsive promoters,
including the use of alternative ubiquitous or tissue-spe-
cific promoters.
Methods
Lentiviral construct and virus production
The Dox-regulated vector system consists of two lenti-
viral vectors, Lenti-ROSA26-rtTA-M2 and Lenti-TetO7/
CMV-EGFP (Figure 1). Both vectors were constructed
using the pC-FUW lentiviral backbone [20]. Lenti-
ROSA26-rtTA-M2 was generated by isolating the
ROSA26-rtTA-M2 sequence from PBII/Rosa26/M2/
HGHpA plasmid (gift from Dr. Richard Chailet, Univer-
sity of Pittsburgh) and ligating this sequence into the
PacI/EcoRI sites of pC-FUW, replacing the original
UBC-EGFP sequence. Lenti-TetO7/CMV-EGFP was gen-
erated by isolating the TetO7/CMV sequence from
pTight-TRE (Clontech, Mountain View, CA) and insert-
ing this sequence into PacI/BamH1 sites of pC-FUW.
The reporter EGFP gene fragment was inserted into
BamH1/EcoR1 sites, which is under control of TetO7/
CMV promoter.
The VSV-G peudotyped lentiviral particles were gen-
erated by using 293FT cells and the ViraPower Lenti-
viral Expression System (Invitrogen, Carlsbad,
California). Lentivirus supernate was collected 72 hours
after transfection, passed through a 0.4 μmf i l t e ru n i t
and concentrated by ultracentrifugation at 50,000 g, 4°C
for 2.5 hours. Pellets were resuspended in 200 ul (1/150
of the original volume) culture medium or PBS. Lenti-
virus titers were determined by p24 ELISA (Cell Biolabs,
Inc, San Diego, CA).
Generation of ROSA26-rtTA-M2 transgenic rats
Female Sprague-Dawley rats (S/D, 4-5 week old) were
superovulated by injection with pregnant mare serum
gonadotropin (PMSG, 20 IU, IP), followed 48 hours
later by injection with human chorionic gonadotropin
(hCG, 20 IU, IP). Immediately after hCG injection,
superovulated females were housed with fertile S/D
males overnight. Females with vaginal plugs were eutha-
nized the next morning for collection of one-cell
embryos. Lentiviral supernate (~10 pl) was injected into
the perivitelline space of the one-cell embryos and the
embryos were cultured overnight in KSOM medium
(Minipore, Billerica, MA) supplemented with essential
amino acids (Invitrogen). Embryos that developed to 2-
cell stage were transferred into the oviducts of peudo-
pregnant recipient rats, as previously described [47]. All
animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Uni-
versity of Pittsburgh, which is the IACUC of record for
Magee-Womens Research Institute (Assurance number
A3654-01), in accordance with the National Institutes of
Health Guidelines for the Care and Use of Laboratory
Animals.
Screening for identification of founder transgenic rats
To identify founder (F0) transgenic rats, tail biopsies
were collected at two weeks of age for genomic DNA
isolation using Gentra Puregene Mouse Tail Kit (Qia-
gen). The resulting genomic DNA samples were
screened by polymerase chain reaction (PCR) and
Southern blot analysis for the rtTA-M2 transgene. The
primers for PCR were: forward, 5’TTACCCGGGGAG-
CATGTCAAGG3’ and reverse, 5’CCACCATGTCTA-
GACTGGACAAGAGC3’. For Southern blot analysis, 15
μg of each DNA sample was digested with EcoR1, elec-
trophoresed on 0.8% agarose gel and transferred to a
Nytran
@Supercharge membrane (Whatman Inc, Sanford,
ME). The membranes were then hybridized overnight at
67°C with Rapid-hyb buffer (Amersham, Piscataway, NJ)
containing labeled rtTA-M2 cDNA (RadPrime DNA
Labeling System kit, Invitrogen).
A portion of each rat tail biopsy was minced and
digested (37°C, 15 min) in 3 ml of 0.25% trypsin (Invi-
trogen) to generate a suspension of tail fibroblasts. The
digestion was terminated by addition of DMEM contain-
ing 10% FBS and the cell suspension was centrifuged
(600 g, 5 min). The resulting cell pellets were resus-
pended in 2 ml DMEM culture medium with 10% FBS
(Hyclone, Logan, Utah). Undigested tissues were allowed
to sediment to the bottom of the tube for two minutes
and supernates were transferred to a 12-well plate to
establish cultures of tail fibroblasts.
The fibroblasts from the rat tails which carried the
rtTA-M2 transgene (determined by PCR genotyping)
were passaged and transduced with Lenti-TetO7/CMV-
EGFP in the presence of 6 μg/ml polybrene (Sigma-
Aldrich, St. Louis, MO). Following transduction,
fibroblasts were maintained in medium containing
doxycycline (Dox, 500 ng/ml, Sigma-Aldrich). Control
cultures for each founder were maintained in medium
without Dox. GFP expression was evaluated 72 hours
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and FITC filter cube. Founders with the highest Dox-
dependent GFP expression were bred with wild type
S/D rats and the offspring were further evaluated by
Southern blot and fibroblast culture to characterize
and segregate individual transgene integrations.
Determination of Lenti-ROSA26-rtTA-M2 integration site
The integration site of the ROSA26-rtTA-M2 trans-
gene was determined by linker-mediated (LM)-PCR
[48,49]. Genomic DNA samples (2 μg) were digested
with NlaIII (20 u) for 1 hour followed by purification
using a PCR clean-up kit (Qiagen, Valencia, CA). The
products were then ligated on each end with a linker
containing T7 and Sp6 promoter sequences (see Addi-
tional File 1: Figure S1, step 2) followed by purification
using the PCR clean-up kit (Qiagen). Primer extension
was performed using the lentiviral vector specific
primers, followed by two rounds of PCR using vector
specific primers and primers from the linker (comple-
mentary to the T7 and Sp6 promoter sequences). The
final PCR products were gel purified and subcloned
into pCR® II-TOPO® vector (Invitrogen) for sequen-
cing. The integration site was determined by analyzing
the sequence with the NCBI Rat Genomic Sequence
Blast tool (http://www.ncbi.nlm.nih.gov/genome/seq/
BlastGen/BlastGen.cgi?taxid=10116, [50]). The details
of these steps and oligonucleotide sequences were
shown in Additional File 1: Figure S1.
Detection of rtTA-M2 expression in tissues
Real Time-polymerase chain reaction (RT-PCR) was
used to detect rtTA-M2 expression in different tissues.
Total RNA from each tissue was extracted by Trizol®
Reagent (Invitrogen). Reverse transcription (RT) was
performed using SuperScript III reverse Transcriptase
(Invitrogen) with Oligo (dT)17.F o rS Y B RG r e e nr e a l -
time PCR, 1 μl of RT product was diluted three times
and used as a template in each reaction. PCR reactions
were performed in triplicate for each tissue sample.
Independent tissue samples were obtained from three
ROSA-rtTA-M2 rats. Primers for rtTA-M2 were for-
ward, 5’AGGCTGGACAAGAGCAAAGT and reverse,
5’ACAGGGTAGGCTGCTCAACT3’. b-actin was ampli-
fied as an internal control using the primers: forward,
5’AGGAGCGTAAAAGTTTCTCCAAG and reverse,
5’CCAGGGATAACTGCAAGGGC3’. The SYBR Green-
based real-time PCR was performed using the LightCy-
cler 4800 real-time PCR system (Roche Applied Science;
Indianapolis, IN). The PCR conditions were as follows:
denature 10 sec at 95°C, anneal 30 sec at 60°C, extend
10 sec at 72°C, repeat 35 cycles. The relative expression
of rtTA-M2 in each tissue was calculated using the
ΔΔCt method where the mean Ct of rtTA-M2 for each
sample was divided by the mean Ct of b-actin for
that sample. The resulting ΔCt values were used to
calculate rtTA-M2 expression in each tissue relative
to rtTA-M2 expressing in the testis using the formula:
2
-ΔCt Transgenic Tissue-ΔCt Transgenic testis.
Western Blot analysis
Fibroblasts were lysed in lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% deox-
ycholate), protein (20 μg) from each sample was sepa-
rated on a 10% denaturing polyacrylamide gel and
transferred to nitrocellulose membranes (Whatman
Inc.). The blots were probed with GFP antibody (Clon-
tech), and reprobed with b-actin antibody (Sigma-
Aldrich). GFP immunoreactivity was detected using the
SuperSignal West Pico Chemiluminescent Substrate
(Piece, Rockford, IL)
In vivo analysis and immunohistochemistry
The transgenic rats were anaesthetized and Lenti-
TetO7/CMV-GFP was injected into skeletal muscle
(hind legs), kidney and testis seminiferous tubules by
efferent duct injection, as previously described [51].
Treated animals were given water containing 0.5 mg/ml
Dox and 2.5% sucrose for 10 days (ad libetum). The
control group was not treated with Dox. Following
treatment, testis tissue was prepared by removing the
tunica albuginea and treating briefly with collagenase IV
(1 mg/ml, Sigma) to disperse seminiferous tubules. Fol-
lowing treatment, GFP expression in whole mount pre-
parations of muscle, kidney and testis tissues was
observed directly, using an epifluorescent microscope
and a FITC/TRITC dual emission filter cube. The dual
emission filter cube is used to distinguish GFP fluores-
cence (green) from autofluorescence (red, [52]). Muscle,
kidney and testis tissues were also fixed with 4% paraf-
ormaldehyde and prepared for immunohistochemical
analysis of GFP expression in section. Tissue sections
(5 μm) were deparaffined, rehydrated and subjected to
antigen retrieval in Sodium Citrate Buffer (10 mM
Sodium Citrate, 0.05% Tween, pH6.0) at 97°C, 30 min-
utes. Sections were hybridized with a mouse anti-EGFP
monoclonal antibody (1:300 dilution, Clontech) for
90 min at room temperature. Normal mouse IgG was used
in place of the anti-EGFP primary antibody for control sec-
tions. Sections were washed (3×) with PBS containing 0.1%
Tween-20 (PBST), followed by incubation with an Alexa
Fluor® 488-conjugated goat anti-mouse secondary antibody
(Invitrogen) for 60 min. Sections were washed and
mounted under glass cover slips with Vectashield mount-
ing medium containing DAPI (Vector Laboratories Inc.,
Burlingame, CA) or Hematoxylin (Sigma).
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Page 10 of 12Additional file 1: Figure S1. Diagram of cloning Lenti-Rosa26-rtTA-
M2 integration site. Genomic DNA is partially digested with Nla III, then
ligated to a linker containing T7 and Sp6 promoter sequences. Provirus
integration site sequence is amplified by primer extension from vector
sequence and followed by two round of PCR with vector specific, T7 and
Sp6 primers. PCR products are gel purified, subcloned into pCR®2.1-
TOPO® and sequenced. A BLAST search of the rat genome was
performed to identify homologous sequence.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-
17-S1.PDF]
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